Last reviewed · How we verify
Bisguadine (ALEXIDINE)
Bisguadine (generic name: ALEXIDINE) is a alexidine drug. It is currently in Phase 2 development.
Bisguadine works by inhibiting phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1, which are enzymes involved in cellular signaling pathways.
Bisguadine is a small molecule with the synonyms ALEXIDINA, ALEXIDINE, COMPOUND 904, and STERWIN 904. Its modality is classified as a small molecule.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ALEXIDINE |
|---|---|
| Drug class | alexidine |
| Target | Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1, Toll-like receptor 9, Beta-lactamase |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 2 |
Mechanism of action
Think of it like a key that unlocks a door. In this case, the key is Bisguadine, and the door is a cellular pathway that's locked by the phosphatase enzymes. By inhibiting these enzymes, Bisguadine can help unlock the pathway and allow the cell to function properly.
Approved indications
Common side effects
Key clinical trials
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous Flap-Based Closure of Pilonidal Disease (NA)
- Hyaluronic Gel vs Chlorhexidine in Periodontal Patients (NA)
- The Aim of This Study is to Compare the Effects of Two Different Topical Agents (KLOROBEN® and KLORHEX PLUS®) Used in the Surgical Extraction of Mandibular Bilateral Mesioangular Impacted Third Molars on Postoperative Pain, Edema, and Trismus. (NA)
- PMPR and Chlorhexidine on Periodontal Disease and Vascular Function (NA)
- Antiplaque Efficacy and Patient Reported Outcome of Chlorohexidine, Cetylpyridinium Chloride, and Essential Oil Mouthwashes in Orthodontic Patients (NA)
- Microbiological Effect of 0.12% Chlorhexidine Digluconate and 0.05% Cetylpyridinium Chloride vs Probiotics (Lactobacillus Reuteri Prodentis) on Porphyromonas Gingivalis. (PHASE4)
- To Compare Post-Extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bisguadine CI brief — competitive landscape report
- Bisguadine updates RSS · CI watch RSS
Frequently asked questions about Bisguadine
What is Bisguadine?
How does Bisguadine work?
What is the generic name of Bisguadine?
What drug class is Bisguadine in?
What development phase is Bisguadine in?
What does Bisguadine target?
Related
- Drug class: All alexidine drugs
- Target: All drugs targeting Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1, Toll-like receptor 9, Beta-lactamase
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing